Generic Korlym Availability
KORLYM (mifepristone - tablet;oral)
Manufacturer: CORCEPT THERAP
Approval date: February 17, 2012
Strength(s): 300MG [RLD]
Has a generic version of Korlym been approved?
No. There is currently no therapeutically equivalent version of Korlym available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Korlym. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists
Issued: December 30, 2014
Assignee(s): Corcept Therapeutics, Inc.
The present invention provides a method for optimizing levels of mifepristone in a patient suffering from a mental disorder amenable to treatment by mifepristone. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng/mL.Patent expiration dates:
- August 27, 2028✓
- August 27, 2028
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- February 17, 2015 -
- February 17, 2019 -
- Korlym Consumer Information (Drugs.com)
- Korlym Consumer Information (Wolters Kluwer)
- Korlym Consumer Information (Cerner Multum)
- Korlym Advanced Consumer Information (Micromedex®)
- Mifepristone Consumer Information (Wolters Kluwer)
- Mifepristone tablets Consumer Information (Wolters Kluwer)
- Mifepristone Consumer Information (Cerner Multum)
- Mifepristone Advanced Consumer Information (Micromedex®)
- Mifepristone AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|